Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US
Esme Needham | January 29, 2026 | Appointment | | Head of Business Development US, Rentschler Biopharma
Rentschler Biopharma has announced the appointment of Detra Glinatsis as Head of Business Development US.
Glinatsis brings more than two decades of expertise in sales and business development to the role. Her experience spans areas including pharmaceutical, biotechnology and contract manufacturing. She was most recently Vice President, Business Development at Northway Biotech. Other previous roles include Head of Sales, Americas at Sartorius and Senior Director, Business Development at AGC Biologics.
This is her second role at Rentschler, having earlier served as Senior Director, Business Development.
The role of Head of Business Development US has been newly created and Glinatsis will take responsibility for US market business development. She will report to the company’s global head of business development, Dr Patrick Meyer.
Meyer said: “[Detra’s] career is a true testament to her expertise, client centric mindset and ability to build long lasting, meaningful partnerships.
“In the past two years, we have successfully transferred one post process performance qualification (PPQ) commercial programme to [the US] site, are advancing three additional programmes toward PPQ and initiated manufacturing for six new products in 2025 – clear proof of the momentum Detra will now help to accelerate. With her commitment to excellence and exceeding client expectations, Detra is the ideal person to lead our US business development activities.”
Rentschler is a contract development and manufacturing organisation (CDMO) focused on providing solutions and support for its clients.
